| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 1951 | 2018 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1850 | 2020 |
| Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies J Naidoo, DB Page, BT Li, LC Connell, K Schindler, ME Lacouture, ... Annals of Oncology 26 (12), 2375-2391, 2015 | 1551 | 2015 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709, 2017 | 1077 | 2017 |
| Genome-wide cell-free DNA fragmentation in patients with cancer S Cristiano, A Leal, J Phallen, J Fiksel, V Adleff, DC Bruhm, SØ Jensen, ... Nature 570 (7761), 385-389, 2019 | 905 | 2019 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of clinical oncology 39 (36), 4073-4126, 2021 | 857 | 2021 |
| Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ... Cancer discovery 7 (3), 264-276, 2017 | 841 | 2017 |
| Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ... Journal of Clinical Oncology 40 (12), 1301, 2022 | 650 | 2022 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 493 | 2019 |
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events JR Brahmer, H Abu-Sbeih, PA Ascierto, J Brufsky, LC Cappelli, ... Journal for immunotherapy of cancer 9 (6), 2021 | 443 | 2021 |
| Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma–like and non–small cell carcinoma–like subsets N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ... Clinical Cancer Research 22 (14), 3618-3629, 2016 | 413 | 2016 |
| Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial C Faivre-Finn, D Vicente, T Kurata, D Planchard, L Paz-Ares, ... Journal of Thoracic Oncology 16 (5), 860-867, 2021 | 403 | 2021 |
| Cardiovascular toxicities associated with immune checkpoint inhibitors JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ... Cardiovascular research 115 (5), 854-868, 2019 | 393 | 2019 |
| Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab LC Cappelli, AK Gutierrez, AN Baer, J Albayda, RL Manno, U Haque, ... Annals of the rheumatic diseases 76 (1), 43-50, 2017 | 384 | 2017 |
| NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 18 (3), 230-241, 2020 | 369 | 2020 |
| Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ... Journal of Thoracic Oncology 13 (12), 1930-1939, 2018 | 359 | 2018 |
| Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities K Suresh, J Naidoo, CT Lin, S Danoff Chest 154 (6), 1416-1423, 2018 | 311 | 2018 |
| Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ... JAMA oncology 6 (12), 1952-1956, 2020 | 310 | 2020 |
| Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ... International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018 | 302 | 2018 |
| Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ... Nature 596 (7870), 126-132, 2021 | 300 | 2021 |
